Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

BG Baumert; ME Hegi; Martin van den Bent; A von Deimling; T Gorlia; K Hoang-Xuan; AA Brandes; G Kantor; MJB Taphoorn; M Ben Hassel; C Hartmann; G Ryan; D Capper; J.M. Kros; S Kurscheid; W Wick; R Enting; M Reni; B Thiessen; F Dhermain; Jacoline Bromberg; L Feuvret; JC Reijneveld; O Chinot; JMM Gijtenbeek; J P Rossiter; N Dif; C Balana; J Bravo-Marques; PM Clement; C Marosi; T Tzuk-Shina; R A Nordal; J Rees; D Lacombe; WP Mason; R Stupp

doi:10.1016/s1470-2045(16)30313-8

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

BG Baumert, ME Hegi, Martin van den Bent, A von Deimling, T Gorlia, K Hoang-Xuan, AA Brandes, G Kantor, MJB Taphoorn, M Ben Hassel, C Hartmann, G Ryan, D Capper, J.M. Kros, S Kurscheid, W Wick, R Enting, M Reni, B Thiessen, F DhermainJacoline Bromberg, L Feuvret, JC Reijneveld, O Chinot, JMM Gijtenbeek, J P Rossiter, N Dif, C Balana, J Bravo-Marques, PM Clement, C Marosi, T Tzuk-Shina, R A Nordal, J Rees, D Lacombe, WP Mason, R Stupp

Research output: Contribution to journal › Article › Academic › peer-review

404 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1521-1532
Number of pages	12
Journal	Lancet Oncology
Volume	17
Issue number	11
DOIs	https://doi.org/10.1016/s1470-2045(16)30313-8
Publication status	Published - 2016

Research programs

EMC MM-03-24-01
EMC MM-03-44-06

Access to Document

10.1016/s1470-2045(16)30313-8

Cite this

Baumert, BG., Hegi, ME., van den Bent, M., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, AA., Kantor, G., Taphoorn, MJB., Ben Hassel, M., Hartmann, C., Ryan, G., Capper, D., Kros, J. M., Kurscheid, S., Wick, W., Enting, R., Reni, M., Thiessen, B., ... Stupp, R. (2016). Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, 17(11), 1521-1532. https://doi.org/10.1016/s1470-2045(16)30313-8

@article{bb0e8381bbdd47108a8b90d5c63a69b8,

title = "Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study",

author = "BG Baumert and ME Hegi and {van den Bent}, Martin and {von Deimling}, A and T Gorlia and K Hoang-Xuan and AA Brandes and G Kantor and MJB Taphoorn and {Ben Hassel}, M and C Hartmann and G Ryan and D Capper and J.M. Kros and S Kurscheid and W Wick and R Enting and M Reni and B Thiessen and F Dhermain and Jacoline Bromberg and L Feuvret and JC Reijneveld and O Chinot and JMM Gijtenbeek and Rossiter, {J P} and N Dif and C Balana and J Bravo-Marques and PM Clement and C Marosi and T Tzuk-Shina and Nordal, {R A} and J Rees and D Lacombe and WP Mason and R Stupp",

year = "2016",

doi = "10.1016/s1470-2045(16)30313-8",

language = "Undefined/Unknown",

volume = "17",

pages = "1521--1532",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "11",

}

Baumert, BG, Hegi, ME, van den Bent, M, von Deimling, A, Gorlia, T, Hoang-Xuan, K, Brandes, AA, Kantor, G, Taphoorn, MJB, Ben Hassel, M, Hartmann, C, Ryan, G, Capper, D, Kros, JM, Kurscheid, S, Wick, W, Enting, R, Reni, M, Thiessen, B, Dhermain, F, Bromberg, J, Feuvret, L, Reijneveld, JC, Chinot, O, Gijtenbeek, JMM, Rossiter, JP, Dif, N, Balana, C, Bravo-Marques, J, Clement, PM, Marosi, C, Tzuk-Shina, T, Nordal, RA, Rees, J, Lacombe, D, Mason, WP & Stupp, R 2016, 'Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study', Lancet Oncology, vol. 17, no. 11, pp. 1521-1532. https://doi.org/10.1016/s1470-2045(16)30313-8

TY - JOUR

T1 - Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

AU - Baumert, BG

AU - Hegi, ME

AU - van den Bent, Martin

AU - von Deimling, A

AU - Gorlia, T

AU - Hoang-Xuan, K

AU - Brandes, AA

AU - Kantor, G

AU - Taphoorn, MJB

AU - Ben Hassel, M

AU - Hartmann, C

AU - Ryan, G

AU - Capper, D

AU - Kros, J.M.

AU - Kurscheid, S

AU - Wick, W

AU - Enting, R

AU - Reni, M

AU - Thiessen, B

AU - Dhermain, F

AU - Bromberg, Jacoline

AU - Feuvret, L

AU - Reijneveld, JC

AU - Chinot, O

AU - Gijtenbeek, JMM

AU - Rossiter, J P

AU - Dif, N

AU - Balana, C

AU - Bravo-Marques, J

AU - Clement, PM

AU - Marosi, C

AU - Tzuk-Shina, T

AU - Nordal, R A

AU - Rees, J

AU - Lacombe, D

AU - Mason, WP

AU - Stupp, R

PY - 2016

Y1 - 2016

U2 - 10.1016/s1470-2045(16)30313-8

DO - 10.1016/s1470-2045(16)30313-8

M3 - Article

SN - 1470-2045

VL - 17

SP - 1521

EP - 1532

JO - Lancet Oncology

JF - Lancet Oncology

IS - 11

ER -